Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
P/B ratio for Altimmune, Inc. (ALT)
P/B ratio as of 2023: 3.09
According to Altimmune, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.09. At the end of 2022 the company had a P/B ratio of 4.17.
P/B ratio history for Altimmune, Inc. from 2005 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.09 |
| 2022 | 4.17 |
| 2021 | 1.90 |
| 2020 | 1.28 |
| 2019 | 0.54 |
| 2018 | 0.12 |
| 2017 | 0.52 |
| 2016 | 1.58 |
| 2015 | 1.71 |
| 2014 | 1.40 |
| 2013 | 3.07 |
| 2012 | 1.84 |
| 2011 | 1.33 |
| 2010 | 1.17 |
| 2009 | 6.50 |
| 2008 | 0.54 |
| 2007 | 0.10 |
| 2006 | 0.00 |
| 2005 | 0.05 |